期刊文献+

PCL基复合骨组织工程支架研究现状及发展 被引量:2

Polycaprolactone-Based Composite Scaffolds in Bone Tissue Engineering:Research Status and Prospect
下载PDF
导出
摘要 三维骨组织工程支架已成为成骨研究领域的热点。聚己内酯(PCL)具有良好的生物相容性,在骨组织工程研究中被广泛应用于三维支架的制备。但纯PCL支架亲水性差、生物活性低,限制了其在生物医学领域的应用。随着骨组织工程材料研究的发展,大量研究者将PCL与各种无机物、金属元素或胶原等活性材料进行复合,以改善支架性能或引入新的性能。针对PCL基骨组织工程复合支架的材料选择,从PCL复合无机材料、PCL复合水凝胶材料、PCL复合金属元素、PCL复合小分子药物以及PCL复合生物活性分子等5个方面,对各类复合支架的性能及体内外成骨效果等方面进行综述,希望对PCL在骨组织工程中的研究及临床应用提供一定的帮助。 Three-dimensional scaffolds have received considerable attention in the field of bone tissue engineering.Polycaprolactone(PCL)is widely used in the preparation of 3 D scaffolds due to its good biocompatibility.However,pure PCL scaffolds have poor hydrophilicity and low biological activity,which limit their application in biomedical field.With the development of bone tissue engineering,a large number of investigations combined PCL with various inorganic substances,metal elements or natural collagen to improve the properties or introduce new properties into the PCL scaffolds.Based on the domestic and foreign literature,in this paper,the selection of materials for PCL bone tissue engineering composite scaffolds was summarized,including inorganic materials,hydrogel materials,metal elements,small molecule drugs and bioactive molecules.The properties and osteogenic effects of the various composite scaffolds were reviewed from five aspects,aiming to provide insights for the research and clinical application of PCL in the bone tissue engineering.
作者 杨湘俊 陈俊宇 朱舟 万乾炳 Yang Xiangjun;Chen Junyu;Zhu Zhou;Wan Qianbing(West China School of Stomatology,Sichuan University,Chengdu 610041,China;West China Hospital of Stomatology,Sichuan University,Chengdu 610041,China)
出处 《中国生物医学工程学报》 CAS CSCD 北大核心 2021年第4期485-492,共8页 Chinese Journal of Biomedical Engineering
基金 国家自然科学基金(81970984,81901060) 四川省科技厅重点研发项目(2019YFS0142)。
关键词 聚己内酯(PCL) 骨组织工程 复合支架 成骨 polycaprolactone(PCL) bone tissue engineering composite osteogenesis
  • 相关文献

参考文献13

二级参考文献116

  • 1谢剑宏,惠忠英,吴渺.羟基化碳纳米管/聚己内酯复合材料的结构和力学性能![J].湖北大学学报(自然科学版),2012,34(4):491-495. 被引量:4
  • 2何大为,金岩,骆凯,李石保.重组人骨形成蛋白-2/转化生长因子-β作用下陶瓷化骨粉/水凝胶与骨髓基质细胞修复自体颅骨缺损[J].中国临床康复,2005,9(46):39-41. 被引量:3
  • 3Berenbaum F. New horizons and perspectives in the treatment of os- teoarthritis [ J ]. Arthritis Res Ther, 2008,10 ( Suppl 2 ) : S 1.
  • 4Fecher LA,Amaravadi RK,Flaherty KT. The MAPK pathway in melanoma[J]. Curr Opin Oneol,2008,20(2) : 183-189.
  • 5Kimura H,Yukitake H,Suzuki H,et al. The chondroproteetive a- gent ITZ-1 inhibits interleukin-lbeta-induced matrix metallopro- teinase-13 production and suppresses nitric oxide-induced chon- drocyte death [ J ]. J Pharmacol Sei, 2009,110 (2) : 201-211.
  • 6Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases [J]. Biochim Biophys Acta,2010,1802(4) :396-405.
  • 7Prasadam I, Friis T, Shi W, et al. Osteoarthritic cartilage chondro- cytes alter subehondral bone osteoblast differentiation via MAPK signalling pathway involving ERK 1/2 [ J ]. Bone, 2010,46 ( 1 ) : 226- 235.
  • 8Chowdhury TT,Salter DM, Bader DL,et al. Signal transduction pathways involving p38 MAPK,JNK,NFkappaB and AP-1 influ- ences the response of chondroeytes cultured in agarose constructs to IL- 1beta and dynamic compression [ J ]. Inflamm Res,2008,57 (7) : 306-313.
  • 9Stoddart M J, Grad S, Eglin D,et al. Cells and biomaterials in carti- lage tissue engineering[ J ]. Regen Med, 2009,4 ( 1 ) : 81-98.
  • 10Murphy G, Kntiuper V,Atkinson S, et al. Matrix metalloproteinases in arthritic disease [ J ]. Arthritis Res, 2002,4 (Suppl 3 ) : S39-49.

共引文献171

同被引文献9

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部